<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e341S-68S. [135 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23649446&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D, American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):277S-89S.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of recommendation (&lt;strong&gt;1A&amp;ndash;2C&lt;/strong&gt;) and the approach to rating the quality of evidence are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Approach to Patients&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations (Adapted From First and Second Editions)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with a good performance status (PS) (i.e., Eastern Cooperative Oncology Group [ECOG] level 0 or 1) and stage IV non-small cell lung cancer (NSCLC), a platinum-based chemotherapy regimen is recommended based on the survival advantage and improvement in quality of life (QOL) over best supportive care (BSC) (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: Patients may be treated with several chemotherapy regimens (carboplatin and cisplatin are acceptable, and can be combined with paclitaxel, docetaxel, gemcitabine, pemetrexed, or vinorelbine).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC and a good PS, two-drug combination chemotherapy is recommended. The addition of a third cytotoxic chemotherapeutic agent is not recommended because it provides no survival benefit and may be harmful (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;First-line Chemotherapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Histology-based Chemotherapy Selection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients receiving palliative chemotherapy for stage IV NSCLC, it is recommended that the choice of chemotherapy is guided by the histologic type of NSCLC (&lt;strong&gt;Grade 1B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: The use of pemetrexed (either alone or in combination) should be limited to patients with non-squamous NSCLC.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: Squamous histology has not been identified as predictive of better response to any particular chemotherapy agent.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Targeted Chemotherapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with known epidermal growth factor receptor (EGFR) mutations and stage IV NSCLC, first-line therapy with an EGFR tyrosine kinase inhibitor (TKI) (gefitinib or erlotinib) is recommended based on superior response rates, progression-free survival (PFS) and toxicity profiles compared with platinum-based doublets (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Use of Vascular Endothelial Growth Factor Inhibitors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Bevacizumab improves survival combined with carboplatin and paclitaxel in a clinically selected subset of patients with stage IV NSCLC and good PS (non-squamous histology, lack of brain metastases, and no hemoptysis). In these patients, addition of bevacizumab to carboplatin and paclitaxel is recommended (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV non-squamous NSCLC and treated, stable brain metastases, who are otherwise candidates for bevacizumab therapy, the addition of bevacizumab to first-line, platinum-based chemotherapy is a safe therapeutic option (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: No recommendation can be given about the use of bevacizumab in patients receiving therapeutic anticoagulation or with an ECOG PS of 2.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Maintenance Chemotherapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Maintenance EGFR TKI Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV non-squamous NSCLC who do not experience disease progression after 4 cycles of platinum-based therapy (which does not include pemetrexed), treatment with switch maintenance pemetrexed is suggested (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC, switch maintenance therapy with chemotherapy agents other than pemetrexed has not demonstrated an improvement in overall survival and is not recommended (&lt;strong&gt;Grade 1B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV non-squamous NSCLC who do not experience disease progression after 4 cycles of platinum-pemetrexed therapy, continuation pemetrexed maintenance therapy is suggested (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC who do not experience disease progression after 4 cycles of platinum-based double agent chemotherapy, maintenance therapy with erlotinib is suggested (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Targeted Therapy Together with Cytotoxic Chemotherapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC the addition of cetuximab in combination with chemotherapy is suggested not to be used outside of a clinical trial (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Second- and Third-line Chemotherapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC who have good PS (ECOG 0-2), second-line treatment with erlotinib or docetaxel (or equivalent single-agent such as pemetrexed) is recommended (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC who have good PS (ECOG 0-2), third-line treatment with erlotinib improves survival compared with BSC and is recommended (&lt;strong&gt;Grade 1B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: No recommendation can be given about the optimal chemotherapeutic strategy in patients with stage IV NSCLC who have received three prior regimens for advanced disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of Elderly Patients&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In elderly patients (age &amp;ge;70&amp;ndash;79 years) with stage IV NSCLC who have good PS and limited comorbidities, treatment with the two drug combination of monthly carboplatin and weekly paclitaxel is recommended (&lt;strong&gt;Grade 1A&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Remark&lt;/em&gt;: In patients with stage IV NSCLC who are 80 years or over, the benefit of chemotherapy is unclear and should be decided based on individual circumstances.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment of Patients with Poor PS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Health-related QOL&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients with stage IV NSCLC with a PS of 2 in whom the PS is caused by the cancer itself, double agent chemotherapy is suggested over single agent chemotherapy (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC who are an ECOG PS of 2 or greater, it is suggested not to add bevacizumab to chemotherapy outside of a clinical trial (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;The Role of Palliative Care in Stage IV NSCLC&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In patients with stage IV NSCLC early initiation of palliative care is suggested to improve both QOL and duration of survival (&lt;strong&gt;Grade 2B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of the Recommendations Grading System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of the Recommendations Grading System&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Grade of Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Benefit vs. Risk and Burdens&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Methodologic Quality of Supporting Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Implications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, high-quality evidence, Grade 1A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consistent evidence from randomized controlled trials (RCTs) without important limitations or exceptionally strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change confidence in the estimate of effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, moderate-quality evidence, Grade 1B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in most circumstances. Higher quality research may well have an important impact on confidence in the estimate of effect and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, low- or very-low-quality evidence, Grade 1C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence for at least one critical outcome from observational studies, case series, or from RCTs with serious flaws or indirect evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, high-quality evidence, Grade 2A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits closely balanced with risks and burden&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consistent evidence from RCTs without important limitations or exceptionally strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The best action may differ depending on circumstances or patient's or societal values. Further research is very unlikely to change confidence in the estimate of effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, moderate-quality evidence, Grade 2B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits closely balanced with risks and burden&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best action may differ depending on circumstances or patient's or societal values. Higher-quality research may well have an important impact on confidence in the estimate of effect and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, low- or very-low-quality evidence, Grade 2C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence for at least one critical outcome from observational studies, case series, or RCTs, with serious flaws or indirect evidence &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Stage IV non-small cell lung cancer (NSCLC) &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Family Practice" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Oncology" />
      <FieldValue Value="Pulmonary Medicine" />
      <FieldValue Value="Radiation Oncology" />
      <FieldValue Value="Thoracic Surgery" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Allied Health Personnel" />
      <FieldValue Value="Health Care Providers" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Patients" />
      <FieldValue Value="Physicians" />
      <FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" />
      <FieldValue Value="Social Workers" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To inform the clinical decisions that must be jointly made by physicians and patients in developing diagnostic, treatment, and management plans so that they can enhance the benefits and reduce the harms associated with various options&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with stage IV non-small cell lung cancer (NSCLC)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;General approach to patients&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Platinum-based chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Two-drug combination chemotherapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;First-line chemotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Histology-based chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Targeted chemotherapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) (gefitinib or erlotinib) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Vascular endothelial growth factor inhibitors (bevacizumab) in combination with other agents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Maintenance chemotherapy (maintenance pemetrexed, maintenance therapy with erlotinib) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cetuximab in combination with chemotherapy (only in clinical trial) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Second- and third-line chemotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Erlotinib &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Docetaxel &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of elderly patients: two drug combination of monthly carboplatin and weekly paclitaxel &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of patients with poor performance status&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Double agent chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Addition of bevacizumab to chemotherapy (only in clinical trial) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Overall survival &lt;/li&gt;&#xA;    &lt;li&gt;Progression-free survival&lt;/li&gt;&#xA;    &lt;li&gt;Quality of life&lt;/li&gt;&#xA;    &lt;li&gt;Toxicity of treatment&lt;/li&gt;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A writing committee was assembled and approved according to American College of Chest Physicians (ACCP) policies as described in the methodology article of the lung cancer guidelines (see the &quot;Availability of Companion Documents&quot; field). This committee, in conjunction with the executive committee, formulated clinical questions in a population, intervention, comparator, and outcome (PICO) format (see Table S1 in the supporting data [see the &quot;Availability of Companion Documents&quot; field]), and the search and study selection was structured around these questions. The primary questions are summarized below:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Should the choice of first-line chemotherapy be based on histology in patients with advanced stage IV non-small cell lung cancer (NSCLC)? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Are epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) a more effective first-line treatment than standard or platinum-based chemotherapy for patients with advanced stage IV NSCLC with EGFR mutations? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is bevacizumab with chemotherapy safe for patients with advanced stage IV NSCLC and treated brain metastases, anticoagulation, or a poor PS than chemotherapy alone? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Do patients with advanced stage IV NSCLC receiving either continuation or switch maintenance chemotherapy have better outcomes than patients receiving no maintenance chemotherapy?&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Do patients with advanced stage IV NSCLC receiving continuation maintenance chemotherapy have better outcomes than patients receiving no maintenance chemotherapy? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Do patients with advanced stage IV NSCLC receiving switch maintenance chemotherapy have better outcomes than patients receiving no chemotherapy? &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Do patients with advanced stage IV NSCLC receiving maintenance EGFR TKIs have better outcomes than patients receiving no chemotherapy? &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is chemotherapy with cetuximab (anti-EGFR antibodies) more effective in improving survival than chemotherapy alone for patients with advanced stage IV NSCLC? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Will second-/third-line chemotherapy lead to better survival than no second-/third-line chemotherapy for patients with advanced stage IV NSCLC with prior therapy? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is doublet chemotherapy more effective than single-agent chemotherapy for patients &amp;gt;70 years of age with advanced stage IV NSCLC? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is doublet chemotherapy more effective than single-agent chemotherapy for patients with a performance status (PS) of 2 with advanced stage IV NSCLC? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is palliative care more effective in improving survival than no palliative care for patients with advanced stage IV NSCLC? &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;To update previously published guidelines for the palliative treatment of stage IV NSCLC, the writing committee repeated prior searches of MEDLINE for studies of therapy for stage IV NSCLC and performed new systematic searches of the PubMed/MEDLINE, EMBASE, and Cochrane databases up to December 2011, limited to research on humans and only articles written in English. Additional articles were identified by searching personal files and by reviewing the reference lists of included studies. Titles and, if relevant, abstracts were reviewed; articles were selected for inclusion if they addressed the population and outcomes of interest. The panel focused primarily on randomized trials, selected meta-analyses, practice guidelines, and reviews. In addition, phase 2 controlled studies that provided relevant information (e.g., for toxicity or particular patient subgroups) were included. Details of the search process are available on request.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Not Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Assessment of Study Quality&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic reviews and meta-analyses were assessed using Documentation and Appraisal Review Tool (DART) (R. L. Diekemper; B. K. Ireland, MD; and L. R. Merz, PhD, MPH, DART, unpublished data, 2012), which was developed as an improved alternative to the existing tools for use in a clinical setting. However, this tool has been adopted for use in American College of Chest Physicians (ACCP) guidelines and consensus statements since 2011.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Quality was assessed for each study as well as for the body of relevant evidence. Based on the population, intervention, comparator, and outcome (PICO) questions and volume of available literature, multiple study designs were included in the systematic reviews of the literature. Randomized controlled trials (RCTs) primarily indicate benefits, but whenever observational studies met inclusion criteria they were often helpful in identifying harms. Observational studies were also examined when RCTs were not available to answer a particular PICO question. Allowing for multiple study designs resulted in the need for multiple quality assessment tools. Tools were chosen for assessing RCTs, observational studies, and diagnostic studies. The quality assessment tool for RCTs (R. L. Diekemper, B. K. Ireland, and L. R. Merz, unpublished data, 2012) was used for assessing the quality of RCTs, and a tool developed by the committee of the ninth edition of the Antithrombotics Guidelines was used for assessing the quality of observational studies. Diagnostic studies were assessed using the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Meta-analyses&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If a recently published good-quality meta-analysis was available, then it was used to inform the recommendations. When a good-quality meta-analysis was not available, guideline authors were encouraged to perform their own meta-analyses. Meta-analyses were performed when the data were fairly homogeneous. If a study was deemed poor quality, then it was not included in the pooled analysis. Heterogeneity of the pooled results was assessed using a &lt;em&gt;&amp;chi;&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; test and Higgins &lt;em&gt;I&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt;, and a forest plot was examined for consistency of the results. The random effects model was chosen a priori as the appropriate model for pooling the data because it accounts for heterogeneity among the included studies. Results from the meta-analyses are available in the supplementary materials that can be downloaded from the Journal website under the corresponding article in the table of contents.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Panel Composition and Responsibilities&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A call for applications to serve on the 3rd edition of the American College of Chest Physicians (ACCP) Lung Cancer Guidelines (LC III) panel was put forth to the ACCP membership, to past panelists, and to other organizations that have previously endorsed earlier editions of these guidelines or appointed representatives to serve on those panels. Guiding the team was the LC III Executive Committee, composed of a Panel Chair, Vice Chair, Liaison to the Guidelines Oversight Committee (GOC), and two staff members, one serving as an adviser and the other as the lead methodologist. The GOC appointed the Liaison and the Chair, who was required to be free of conflicts of interest (COI). This Executive Committee provided general oversight and guidance; multiple reviews of research questions, article outlines, manuscripts, evidence tables, and other supporting documents; and facilitation of the final conference discussions and voting. As the scope was defined, content experts in each major area were identified to serve as topic editors and nominated by the Panel Chair to be advanced to the GOC for the requisite qualifications and COI review and approval process. These topic editors organized their research and writing teams, oversaw the work of the individual members, edited separate contributions into synthesized manuscripts, presented evidence at the final conference, and managed any of their committee members who were approved with management stipulations relevant to their COIs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each topic editor was initially charged with proposing individuals to support their topic committees with expertise in the content area and/or methodology. With the Chair's approval, these individuals were nominated for GOC reviews for COI and expertise. In some cases, GOC staff helped to locate additional methodologic support when it was determined to be necessary for various article committees. This resulted in an international panel of &amp;gt;100 multidisciplinary experts across 24 articles representing the fields of pulmonary medicine, critical care medicine, thoracic surgery, medical and radiation oncology, pathology, integrative medicine, primary care, health-care research, guidelines methodology, and epidemiology. Nineteen international organizations that are also dedicated to advancing research and practice in the area of lung cancer were invited to appoint representatives to this guideline project as adjunct participants. These individuals, unless already approved panelists, were not considered full voting members of the panel, since they had not been through the same ACCP COI review, but were included at the final conference, participated fully in the discussions, and provided external review and feedback on the manuscripts and supporting documentation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Formulating the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In most cases the topic editors, along with the other completely non-conflicted members of the article committee, formulated the recommendations. The summarized evidence tables and profiles (where profiles existed) provided the foundation for the recommendations. In formulating the recommendations, panelists considered not only the body of evidence but also the balance between the benefits and harms and considerations of other factors, such as cost or resource availability considerations and patient values and preferences, which might vary widely for some recommendations. These additional considerations are described in a Remarks section, which appears just below the relevant recommendation in the publication, each time the recommendation appears.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations that are strong must be differentiated from those that are weak or weaker. Thus, the ACCP Grading System was used (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field), and the wording of the recommendations is explicit. This grading system has been used since 2005 and is based on two dimensions: the balance of benefits to harms and the quality of the evidence base. If the benefits clearly outweigh the harms or the harms clearly outweigh the benefits, the strength of the recommendation is considered strong and graded as a 1. In most cases, when there is strong confidence that the benefits outweigh the harms, most patients would choose the intervention endorsed in that recommendation. However, when the tradeoffs between desirable and undesirable consequences are not as clear, variability in patient preferences and values often becomes germane to the decision-making conversation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Weak recommendations are those for which the benefits and harms are more equally balanced, and thus a clear choice is not as obvious; these are graded with a 2. Strong recommendations are phrased, &quot;the panel recommends,&quot; whereas weak recommendations are phrased &quot;the panel suggests.&quot; Accompanying these indications of the strength of a recommendation is a letter score (A, B, or C) representing the grading of the body of relevant literature.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In grading the quality of the evidence, RCTs start with a high score but might be downgraded to moderate or even low based on the following criteria: limitations in the study design or conduct of the trial, imprecision, indirectness relative to the specifics of the PICO question, inconsistency in the results, and risk of reporting bias. Observational studies, on the other hand, start off as low-level evidence but can be upgraded to moderate or even high if exceptionally large and consistent treatment effects increase confidence in the findings, especially if there is a strong dose-response gradient.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The final grades are combinations reflecting the strength of the recommendation and the quality of the evidence. Strong recommendations with high quality evidence, grade of 1A, are less common than in past editions of these guidelines, since the evidence is assessed with greater rigor for most topics, and few studies without important limitations are available.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;However, recommendations that do attain this score are those for which the panel could state with confidence that new studies would be unlikely to change the direction of the effect. These recommendations apply to most patients in most circumstances. But as the grades decline, patient values and preferences likely would play an increasingly greater role in determining the best treatments or interventions for each patient.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The Final Conference&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As the evidence reviews were completed and the tables and profiles prepared, the manuscripts and recommendations were drafted. Members of the article committees convened by phone or e-mail to discuss the evidence and work on drafting and grading the recommendations. These discussions generally resulted in agreement on both the quality of the evidence and strength of the recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The manuscripts and supporting tables were then reviewed by members of the Executive Committee and, after several iterations, the revised versions were shared among all panelists and the representatives of invited organizations in advance of the conference. The other panelists and representatives were asked not only to provide feedback but also to review the recommendations to identify any controversies. A recommendation was deemed to be controversial if at least one person disagreed with the wording or the grading, if there was controversy in practice, if there were wide variations in practice, or if at least one person asked that it be discussed among the broader panel and association representatives. These identified controversies composed the main agenda for the conference.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See the &quot;Methodology for Development of Guidelines for Lung Cancer&quot; (see the &quot;Availability of Companion Documents&quot; field) for more information.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of the Recommendations Grading System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Strength of the Recommendations Grading System&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Grade of Recommendation&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Benefit vs. Risk and Burdens&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Methodologic Quality of Supporting Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Implications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, high-quality evidence, Grade 1A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consistent evidence from randomized controlled trials (RCTs) without important limitations or exceptionally strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change confidence in the estimate of effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, moderate-quality evidence, Grade 1B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in most circumstances. Higher quality research may well have an important impact on confidence in the estimate of effect and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Strong recommendation, low- or very-low-quality evidence, Grade 1C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits clearly outweigh risk and burdens or vice versa&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence for at least one critical outcome from observational studies, case series, or from RCTs with serious flaws or indirect evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, high-quality evidence, Grade 2A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits closely balanced with risks and burden&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consistent evidence from RCTs without important limitations or exceptionally strong evidence from observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The best action may differ depending on circumstances or patient's or societal values. Further research is very unlikely to change confidence in the estimate of effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, moderate-quality evidence, Grade 2B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Benefits closely balanced with risks and burden&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Best action may differ depending on circumstances or patient's or societal values. Higher-quality research may well have an important impact on confidence in the estimate of effect and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;Weak recommendation, low- or very-low-quality evidence, Grade 2C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence for at least one critical outcome from observational studies, case series, or RCTs, with serious flaws or indirect evidence &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on confidence in the estimate of effect and may well change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Chest Physicians (ACCP) guidelines include consideration of resources in recommendations under selected circumstances. If it is likely that resource considerations would impact the direction or strength of a recommendation, a search for cost-effectiveness studies may have been conducted. Most recommendations in these guidelines do not include a full assessment of resource considerations. However, they can be adapted to middle- and low-income countries using the ADAPTE strategies.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Internal and External Peer Review&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once Executive Committee approval was received, the articles were submitted to American College of Chest Physicians (ACCP) staff for several layers of review. All reviewers were required to undergo a full conflict of interest (COI) appraisal before being approved. In the first round of reviews, the Thoracic Oncology NetWork reviewed the content of the manuscripts and the members of the Guidelines Oversight Committee (GOC) assessed the manuscripts for adherence to the methodology and conformance with the evidence. The ACCP President also appointed members of the Board of Regents to evaluate the guidelines in depth. All comments were collated into spreadsheets to ensure that they were appropriately answered. GOC and board reviewers discussed each comment and determined which should be mandatory for the authors to amend and which were provided as suggestions for improvement. All reviews and comments were anonymous, and authors were required to respond to all mandatory issues either by revising the manuscripts or providing written justification explaining why they did not agree with the reviewers' comments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The revised manuscripts were submitted for round II review, simultaneously with the Journal peer review. Once the GOC and board reviewers approved the manuscripts, the ACCP President, President Elect, President Elect Designee, and Immediate Past President reviewed the guidelines. Approval was granted pending confirmation from the Board of Regents, before submission to the journal for final review by the Journal Editor. In addition to this extensive review process, which included nearly 30 individual reviewers from the ACCP leadership, external organizations were provided with opportunities to provide feedback before, during, and just after the conference. This final version was submitted for consideration for endorsement to all of the invited organizations, whether or not they sent representatives to the conference. However, once the guidelines were approved by the ACCP Board of Regents, no further changes were accepted. Organizations that provided endorsements are listed in each article.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate treatment of patients with stage IV non-small cell lung cancer (NSCLC)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Toxicity&amp;nbsp;of chemotherapy&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;American College of Chest Physicians (ACCP) guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at the &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1682324&quot; title=&quot;Chest Web site&quot;&gt;&lt;em&gt;CHEST&lt;/em&gt; Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although the ACCP is moving toward the production of evidence profiles for all guideline recommendations, there were many recommendations for which profiles were not developed, mostly because of resource constraints. When possible, methodologists created evidence profiles, and all panelists were educated on how to read and interpret them. The population, intervention, comparator, and outcome (PICO)-based systematic literature review process was followed for most recommendations, but there were some that could have benefited from meta-analyses. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One limitation of all guidelines today is that they are not able to adequately address complex patients with multiple morbidities. This is largely because these patients are generally excluded from clinical trials and are often not included in observational studies. Since guidelines are reliant on evidence published in the peer-reviewed literature, the scientific foundation impedes the process of providing good guidance for these patients and is a limitation in these guidelines. Therefore, the ACCP encourages funding agencies to ensure that topics with limited evidence are addressed in future research. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Dissemination and Implementation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;These guidelines are widely disseminated through the &lt;em&gt;CHEST&lt;/em&gt; journal publication, National Guideline Clearinghouse, and Guidelines International Network library. Additional clinical resources will soon be available to users of CHEST Evidence, an upcoming tool for searching the content of America College of Chest Physicians (ACCP) guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As the expanding research into diagnostic techniques and treatment options continues to evolve, the guidelines must be updated and kept current. This edition of the ACCP Lung Cancer Guidelines will be the last to be published as a complete collection, as the ACCP is now embarking on a new living guidelines model (LGM) for revising existing recommendations and developing new recommendations as the literature evolves. This will include a continual assessment of the currency of these recommendations relevant to new research studies as they are published. The review cycle for the ACCP Lung Cancer Guidelines will begin 1 year after publication unless the content experts who monitor the literature bring a recommendation or set of related recommendations to the attention of the Guideline oversight Committee (GOC), suggesting that those recommendations are in need of updating sooner. The new LGM will permit a more nimble approach to guideline development but also requires a point-of-care accessible vehicle, CHEST Evidence, for the users to readily search for the most current version. These features will be described in greater detail in upcoming publications. As a step in this direction, these guidelines will be published primarily online with a printed version of the Executive Summary, containing all of the recommendations, the introduction, and this article on methodology. All narratives for each article with their supporting tables, figures, and algorithms will be available online at &lt;a href=&quot;http://journal.publications.chestnet.org/&quot; title=&quot;Chest Journal Web site&quot;&gt;journal.publications.chestnet.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many">
      <FieldValue Value="Mobile Device Resources" />
      <FieldValue Value="Patient Resources" />
      <FieldValue Value="Quick Reference Guides/Physician Guides" />
      <FieldValue Value="Resources" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="End of Life Care" />
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
      <FieldValue Value="Patient-centeredness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e341S-68S. [135 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23649446&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2003 Jan (revised 2013 May)" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American College of Chest Physicians - Medical Specialty Society" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The development of this guideline was supported primarily by the American College of Chest Physicians (ACCP). The lung cancer guidelines conference was supported in part by a grant from the Lung Cancer Research Foundation. The publication and dissemination of the guidelines was supported in part by a 2009 independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Role of sponsors: The ACCP was solely responsible for the development of these guidelines. The remaining supporters played no role in the development process. External supporting organizations cannot recommend panelists or topics, nor are they allowed prepublication access to the manuscripts and recommendations. Further details on the Conflict of Interest (COI) Policy are available online at &lt;a href=&quot;http://chestnet.org&quot; tilte=&quot;Chest Journal Web site&quot;&gt;http://chestnet.org&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;See the methodology companion (see the &quot;Availability of Companion Documents&quot; field) for a complete discussion of the source of funding for this guideline. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Chest Physicians (ACCP) Expert Panel on Lung Cancer Guidelines&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Mark A. Socinski, MD, FCCP; Tracey Evans, MD; Scott Gettinger, MD; Thomas A. Hensing, MD, FCCP; Lecia VanDam Sequist, MD, MPH; Belinda Ireland, MD; Thomas E. Stinchcombe, MD&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Conflicts of Interest (COI) grids reflecting the conflicts of interest that were current as of the date of the conference and voting are posted in the online supplementary materials. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Financial/nonfinancial disclosures: The authors have reported to &lt;em&gt;CHEST&lt;/em&gt; the following conflicts of interest: Dr Evans has served as a consultant to Genentech and Lilly Pharmaceuticals within the past 3 years. Dr Evans's husband serves on the speakers' board for Genentech. Dr VanDam Sequist has performed paid consulting for GlaxoSmithKline and Clovis Pharmaceuticals. Dr Socinski has performed unpaid consulting for Boehringer-Ingelheim; Daiichi Sankyo, Inc; and Merrimack Pharmaceuticals Inc. Drs Gettinger, Hensing, Ireland, and Stinchcombe have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;See the methodology companion (see the &quot;Availability of Companion Documents&quot; field) for a complete discussion of the conflict of interest procedures and requirements for the guideline panel. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist">
      <FieldValue Value="American Association for Bronchology and Interventional Pulmonology - Medical Specialty Society" />
      <FieldValue Value="European Society of Thoracic Surgeons - Professional Association" />
      <FieldValue Value="Oncology Nursing Society - Professional Association" />
      <FieldValue Value="Society of Thoracic Surgeons - Medical Specialty Society" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D, American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):277S-89S.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available to subscribers of &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685295&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal&lt;/a&gt;. Also available to Chest subscribers through the &lt;a href=&quot;http://www.chestnet.org/Publications/Mobile-Offerings/CHEST-App&quot; title=&quot;ACCP Web site&quot;&gt;Chest app&lt;/a&gt; for iPhone and iPad.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American College of Chest Physicians, Products and Registration Division, 3300 Dundee Road, Northbrook IL 60062-2348.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Supporting data. Available to subscribers of &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685295&amp;amp;atab=10&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Detterbeck FC, Zelman Lewis S, Diekemper R, Addrizzo-Harris D, Alberts MW. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Executive summary. Chest 2013 May;143(5 Suppl):7S-37S. Available from the &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685102&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alberts WM. Introduction to the third edition: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013 May;143(5 Suppl):38S-40S. Available from the &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1682326&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Zelman Lewis S, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013 May;143(5 Suppl):41S-e50S. Available from the &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685829&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013 May;143(5 Suppl):e1S-e29S. Available to subscribers of &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685278&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nana-Sinkham SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013 May;143(5 Suppl):e30S-e39S. Available to subscribers of &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1682710&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013 May;143(5 Suppl):e191S-e210S. Available to subscribers of &lt;a href=&quot;http://journal.publications.chestnet.org/article.aspx?articleid=1685290&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American College of Chest Physicians, Products and Registration Division, 3300 Dundee Road, Northbrook IL 60062-2348.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following is also available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Highlights of the ACCP diagnosis and management of lung cancer guidelines, 3rd ed. Podcast. Available from the &lt;a href=&quot;http://journal.publications.chestnet.org/ss/podcasts.aspx#May2013podcasta&quot; title=&quot;Chest Journal Web site&quot;&gt;Chest - The Cardiopulmonary and Critical Care Journal Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;A lung cancer staging calculator is available from the &lt;a href=&quot;http://staginglungcancer.org/&quot; title=&quot;Staging Lung Cancer Web site&quot;&gt;Staging Lung Cancer Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lung cancer: understanding the diagnosis. Northbrook (IL): American College of Chest Physicians; 2010. 7 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://onebreath.org/document.doc?id=40&quot; title=&quot;One Breath Web site&quot;&gt;OneBreath.org Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Understanding non-small cell lung cancer. A guide for the patient. Northbrook (IL): American College of Chest Physicians; 2010. 13 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://onebreath.org/document.doc?id=27&quot; title=&quot;One Breath Web site&quot;&gt;OneBreath.org Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on September 3, 2003. The information was verified by the guideline developer on October 1, 2003. This summary was updated by ECRI Institute on November 27, 2007. The updated information was verified by the guideline developer on December 21, 2007. This summary was updated by ECRI Institute on August 21, 2013. This summary was updated by ECRI Institute on July 18, 2014 following the U.S. Food and Drug Administration advisory on Docetaxel.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>